Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma After Progression on Standard Systemic Therapy

NCT04550624 is registered in ClinicalTrials.gov with Shanghai Jiahui International Hospital as lead sponsor.

NCT NCT04550624
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04550624 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With Advanced Biliary Tract Carcinoma After Progression on Standard Systemic Therapy
Lead sponsor
Shanghai Jiahui International Hospital
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2021
Completion date
December 2, 2025
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced biliary tract carcinoma